Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM09 Dose Finding for Mite-Induced Rhinitis/Rhinoconjunctivitis
NCT02661854Phase 2Unknown
- Sponsor
- Inmunotek
- Start
- Jun 2016
- Primary completion
- Jul 2020
- Modality
- Split/Subunit Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Clustoid MM09 in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (9 arms), sponsored by Inmunotek. Primary endpoint: Concentration required to elicit a positive response after nasal provocation test at 4 months. Status: unknown.
02
Drugs
Clustoid MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02661854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661854.